Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
Berlin, Germany / Garching / Munich, January 13, 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of a supply agreement for non-carrier-added (n.c.a.) Actinium-225 (Ac-225) to support the development of Ariceum’s novel targeted radiopharmaceutical therapies (RPT) pipeline, including lead radiopharmaceutical drug, satoreotide for the treatment of aggressive, difficult-to-treat cancers.